Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Abide Therapeutics
Biotech
Lundbeck slashes value of $250M Abide buyout after pain setback
Lundbeck is slashing the book value of its $250 million Abide buyout in response to phase 1 data that triggered an early end to a pain program.
Nick Paul Taylor
Oct 24, 2024 7:20am
Lundbeck strikes $250M Abide buyout, bagging Tourette's drug
May 6, 2019 8:22am
Celgene drops option to buy Abide, bags preclinical drug
Mar 28, 2018 8:45am
Celgene pays $20M to San Diego startup to option neuro candidate
Sep 29, 2016 8:00am
